NCT07265947Phase 2Recruiting

Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma

Study sponsor: Tyra Biosciences, Inc · TYRA

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2030-10Estimated

Enrollment · participants230Estimated

Source updated2026-09-28Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-01-16 · 1 field changed

Recruitment status changed

− Before

~~Not yet recruiting~~

+ After

Recruiting

Check registry source

Study details

Conditions studied

Low Grade Upper Tract Urothelial Carcinoma

Treatments or interventions studied

Dabogratinib (TYRA-300) 60mgDrugAlso known as TYRA-300
Dabogratinib (TYRA-300) 80mgDrugAlso known as TYRA-300
Dabogratinib (TYRA-300) TBDDrugAlso known as TYRA-300

Primary outcomes · main study measures

measure: To assess the efficacy of Dabogratinib in LG UTUC FGFR3+ participants (proportion of participants with a CR within 6 months out of all LG UTUC FGFR3+ participants); description: Complete response (CR) rate; timeFrame: within 6 months

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history